DRREDDY · Healthcare
Dr. Reddy's Laboratories Ltd. reported revenue of ₹8,100 cr for April to June 2026, −5.5% on the year and +7.3% on the quarter. That is slower than this quarter has grown in recent years (+12.6% on average). Over the last four quarters revenue comes to ₹33,227 cr, −0.9% on the four before.
Operating profit (EBITDA) was ₹860 cr, a margin of 10.6%, −1,474 bps on the year and +555 bps on the quarter. Over the last 8 quarters the margin has ranged from 5.1% to 27.1%, averaging 20.2%. Operating costs grew +13.2%, faster than revenue at −5.5%, so operating profit grew less than sales.
Net profit was ₹436 cr, −69.1% on the year and +97.3% on the quarter, with earnings per share of ₹5.32. Profit before other income, one-offs and tax fell 87.8%, so 19 points of the headline growth came from outside the core business. The tax rate of 21% is in line with its recent average. Profit over the last four quarters totals ₹3,184 cr, −44.6% on the four before.
On earnings per share of ₹38.61 over the last four quarters, the stock at ₹1,229.70 trades at 31.8 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
Half or more of pre-tax profit came from other income. What is it, and does it repeat?
Other income was 64% of profit before tax, against 15% a year earlier.
Source: Quarterly statements
Operating margin fell sharply on the year. Pricing, input costs, or mix?
EBITDA margin 10.6%, −1,474 bps on the year (+555 bps on the quarter).
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,903 cr | ₹7,237 cr | ₹7,114 cr | ₹7,696 cr | ₹8,038 cr | ₹8,381 cr | ₹8,528 cr | ₹8,572 cr | ₹8,828 cr | ₹8,753 cr | ₹7,546 cr | ₹8,100 cr |
| YoY | — | — | — | +14% | +16% | +16% | +20% | +11% | +10% | +4% | −12% | −6% |
| EBITDA margin | 29.1% | 28.0% | 25.7% | 27.7% | 25.8% | 27.1% | 23.4% | 25.4% | 22.8% | 21.6% | 5.1% | 10.6% |
| Other income, % of PBT | 17% | 12% | 13% | 10% | 16% | 8% | 26% | 15% | 19% | 18% | 240% | 64% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | −11% | 21% |
| Net profit | ₹1,482 cr | ₹1,381 cr | ₹1,310 cr | ₹1,392 cr | ₹1,342 cr | ₹1,404 cr | ₹1,587 cr | ₹1,410 cr | ₹1,337 cr | ₹1,190 cr | ₹221 cr | ₹436 cr |
| YoY | — | — | — | −1% | −9% | +2% | +21% | +1% | −0% | −15% | −86% | −69% |
| Core profit YoY | — | — | — | +1% | +0% | +7% | +5% | −4% | −12% | −26% | −119% | −88% |
| EPS | ₹17.77 | ₹16.56 | ₹15.70 | ₹16.69 | ₹15.05 | ₹16.94 | ₹19.09 | ₹16.99 | ₹16.14 | ₹14.50 | ₹2.65 | ₹5.32 |
| Flags | · | · | · | ✓ | 1 | ✓ | 1 | ✓ | 1 | 1 | 4 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Dr. Reddy's Laboratories Ltd. reported revenue of ₹8,100 cr (−5.5% on the year) and net profit of ₹436 cr (−69.1% on the year) for April to June 2026.
Profit before other income, exceptional items and tax moved −87.8% on the year, against −69.1% for reported profit.
2 checks raised a question: Half or more of pre-tax profit came from other income. What is it, and does it repeat?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.